miR-17-5p Promotes Glucose Uptake of HTR8/SVneo Trophoblast Cells by Inhibiting TXNIP/NLRP3 Inflammasome Pathway
Yi Jiang,Lijie Wei,Huiting Zhang,Yuting Chen,Peng Gao,Jingyi Zhang,Xuan Zhou,Shenglan Zhu,Yuanyuan Du,Chenyun Fang,Jiaqi Li,Ling Feng,Mengzhou He,Shaoshuai Wang,Jun Yu
DOI: https://doi.org/10.2147/DMSO.S385774
2022-11-01
Abstract:Yi Jiang, 1 Lijie Wei, 1 Huiting Zhang, 1 Yuting Chen, 1 Peng Gao, 1 Jingyi Zhang, 1 Xuan Zhou, 1 Shenglan Zhu, 1 Yuanyuan Du, 1 Chenyun Fang, 1 Jiaqi Li, 2 Ling Feng, 1 Mengzhou He, 1 Shaoshuai Wang, 1 Jun Yu 1 1 Department of Obstetrics and Gynecology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, 430030, People's Republic of China; 2 Department of Obstetrics and Gynecology, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, 33006, People's Republic of China Correspondence: Jun Yu, Department of Obstetrics and Gynecology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, No. 1095 Jiefang Avenue, Qiaokou District, Wuhan, Hubei Province, People's Republic of China, Email Introduction: Gestational diabetes mellitus (GDM) is one of the common metabolic disorders of pregnancy and results in poor pregnancy outcomes for both mother and fetus. MiR-17-5p is considered as the strongest predictor of metabolic syndrome status, but the relationship between GDM and miR-17-5p remains unclear. TXNIP, which leads to activation of NLRP3, is considered as a potential target of miR-17-5p, and the miR-17-5p/TXNIP/NLRP3 axis has been shown to play a major role in the occurrence and development of many metabolic diseases but has not been validated in GDM. Methods: MiR-17-5p was detected by RT-qPCR. The expression of TXNIP and NLRP3 in placenta was detected by immunofluorescence, RT-qPCR and Western blot. To explore the effect of miR-17-5p on TXNIP and NLRP3 and glucose uptake of HTR8/SVneo cells, miR-17-5p mimic and miR-17-5p inhibitor were transfected to achieve overexpression and inhibition. The interaction between miR-17-5p and TXNIP was confirmed by dual-luciferase reporter assay. Besides, glucose consumption of trophoblast cells was detected by glucose assay kit. Results: MiR-17-5p expression was down-regulated, while the expression of TXNIP and NLRP3 was up-regulated in GDM placental tissues. MiR-17-5p targeted TXNIP and inhibited its expression. MiR-17-5p also regulated NLRP3 expression and glucose uptake of HTR8/SVneo cells, which could be reversed by overexpression of TXNIP, suggesting that miR-17-5p improved glucose uptake of HTR8/SVneo cells by TXNIP/NLRP3 axis. The results were consistent with the above findings in high-glucose treated HTR8/SVneo cells. Conclusion: Our results suggested that miR-17-5p ameliorates the glucose uptake of HTR8/SVneo cells by TXNIP/NLRP3 axis, which may provide a new idea for offspring health of GDM patients. Keywords: diabetes, gestational, microRNAs, pregnancy, inflammation Gestational diabetes mellitus (GDM), which is defined as a state of glucose intolerance first detected during pregnancy, is one of the common metabolic disorders of pregnancy and results in poor pregnancy outcomes for both mother and fetus. According to the 15 centers involved in the Hyperglycemia and Adverse Pregnancy Outcomes (HAPO) study, the worldwide prevalence of GDM ranged from 9% to 26%, with an average of 18%. 1 Lots of complications are associated with GDM, like offspring complications (macrosomia, preterm birth, neonatal hypoglycemia, and so on) and maternal complications (gestational hypertension, preeclampsia, and so on). 2–7 Although the molecular mechanisms of GDM are still not clear, tissue insulin resistance is considered as a critical part of the pathophysiology of GDM, 8 and the impaired glucose uptake of GDM is associated with insulin resistance. Compared with normal pregnancy, the rate of glucose uptake of GDM decreased by 54%, 9 which results in a high-glucose environment in utero. The fetus exposed to high levels of intrauterine glucose may develop a variety of diseases, including preterm birth, miscarriage, macrosomia, intrauterine growth retardation, obesity and type 2 diabetes mellitus later in life. 10 Therefore, ameliorating glucose uptake and alleviating insulin resistance of GDM play a key role in the treatment of GDM. MicroRNA (miRNA) is a type of non-coding RNA, which is small (20–23nt long), highly conserved and endogenous. Via specifically binding to the 3' untranslated region (3'-UTR), miRNA induces target gene mRNA translational inhibition or degradation, 11 which has been shown to be closely related to the development of some diseases, including GDM. The role of some miRNAs in GDM has been studied. For example, miR-98 directly regulated Mecp2/Trpc3 axis, which was considered as a major signal of insulin-mediated glucose uptake. 12 Besides, miR- -Abstract Truncated-
endocrinology & metabolism